Clearbridge Investments LLC Has $10.67 Million Stake in Celcuity, Inc. $CELC

Clearbridge Investments LLC trimmed its position in shares of Celcuity, Inc. (NASDAQ:CELC) by 20.3% during the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 106,931 shares of the company’s stock after selling 27,289 shares during the quarter. Clearbridge Investments LLC owned 0.23% of Celcuity worth $10,665,000 at the end of the most recent reporting period.

Other hedge funds have also recently made changes to their positions in the company. Vanguard Group Inc. grew its holdings in shares of Celcuity by 23.5% during the third quarter. Vanguard Group Inc. now owns 2,059,047 shares of the company’s stock valued at $101,717,000 after buying an additional 391,262 shares during the last quarter. Choreo LLC bought a new position in shares of Celcuity in the third quarter valued at approximately $248,000. TD Asset Management Inc bought a new position in shares of Celcuity in the third quarter valued at approximately $3,596,000. Jennison Associates LLC bought a new position in shares of Celcuity in the fourth quarter valued at approximately $22,911,000. Finally, Tudor Investment Corp ET AL purchased a new stake in Celcuity in the 3rd quarter valued at $1,351,000. 63.33% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of research firms recently commented on CELC. Macquarie Infrastructure set a $160.00 price target on Celcuity in a research report on Thursday, May 28th. Guggenheim reissued a “buy” rating on shares of Celcuity in a research report on Wednesday, June 3rd. Wolfe Research reissued an “outperform” rating and issued a $110.00 price target on shares of Celcuity in a research report on Thursday, March 12th. HC Wainwright lowered their price target on Celcuity from $185.00 to $145.00 and set a “buy” rating for the company in a research report on Wednesday, June 3rd. Finally, Needham & Company LLC restated a “buy” rating and set a $157.00 price target on shares of Celcuity in a report on Friday, May 15th. Eleven investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat, Celcuity presently has an average rating of “Moderate Buy” and a consensus target price of $152.09.

Celcuity Price Performance

Shares of NASDAQ:CELC opened at $88.24 on Thursday. The company’s 50-day moving average is $120.79 and its 200 day moving average is $111.44. The company has a debt-to-equity ratio of 6.04, a quick ratio of 12.31 and a current ratio of 12.31. The company has a market capitalization of $4.30 billion, a P/E ratio of -22.63 and a beta of 0.10. Celcuity, Inc. has a fifty-two week low of $11.27 and a fifty-two week high of $151.02.

Celcuity (NASDAQ:CELC) last issued its quarterly earnings results on Thursday, May 14th. The company reported ($0.97) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.07) by $0.10. On average, equities research analysts forecast that Celcuity, Inc. will post -3.69 earnings per share for the current year.

Insider Activity at Celcuity

In other news, Director David Dalvey sold 25,000 shares of the company’s stock in a transaction on Monday, May 4th. The stock was sold at an average price of $140.68, for a total transaction of $3,517,000.00. Following the transaction, the director owned 65,000 shares of the company’s stock, valued at $9,144,200. This represents a 27.78% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Richard E. Buller sold 9,000 shares of the company’s stock in a transaction on Monday, May 4th. The shares were sold at an average price of $140.46, for a total value of $1,264,140.00. Following the transaction, the director directly owned 6,760 shares in the company, valued at $949,509.60. This represents a 57.11% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last 90 days, insiders have sold 37,000 shares of company stock valued at $5,111,950. 13.33% of the stock is currently owned by company insiders.

About Celcuity

Celcuity, Inc is a clinical-stage biotechnology company specializing in precision oncology diagnostics. The company develops and commercializes predictive biomarker assays designed to identify which patients are most likely to benefit from targeted cancer therapies. By integrating functional profiling of tumor cells with molecular analyses, Celcuity seeks to optimize treatment selection and improve outcomes for patients with solid tumors.

Celcuity’s proprietary platform evaluates tumor cell sensitivity to various therapeutic agents using ex vivo assays that measure DNA damage response and other critical pathways.